文献速递临床免疫质量管理与危急值

甲状腺癌生物标志物的演变:从实验室检测到患者临床管理

Evolution of thyroid cancer biomarkers: from laboratory test to patients' clinical management.
PubMed 文献 · Clin Chem Lab Med · 2022-11-11

本文批判性综述了甲状腺球蛋白(Tg)和降钙素(CT)在分化型与髓样甲状腺癌诊断/监测中的主要问题,并识别新型实验室标志物在临床管理中的优势与挑战。Tg和CT检测的协调性不足及结果与截断值缺乏互换性给程序与方法的可比性和标准化带来挑战,而降钙素原(PCT)或Tg倍增时间等新方法已被证明有效。临床医生与实验室专家的紧密合作对于将当前检测的优势与局限性转化为适当的临床解释标准仍至关重要。

要点

  • Tg和CT检测的协调性不足及结果与截断值缺乏互换性影响可比性与标准化。
  • PCT或Tg倍增时间等新诊断与监测方法已被证明有效。
  • 临床医生与实验室专家的紧密合作对临床解释标准的转化至关重要。

核心结论

  • Tg和CT检测的协调性不足及缺乏互换性挑战可比性与标准化,需临床与实验室紧密合作转化解释标准。

研究设计与样本

  • 综述性研究,批判性回顾当前Tg和CT生物标志物在DTC和MTC诊断/监测中的主要问题。

主要发现

  • Tg和CT检测的协调性不足及实验室结果与截断值缺乏互换性,给程序与方法的可比性和标准化带来挑战。
  • PCT或Tg倍增时间等新诊断与监测方法已被证明有效。

临床怎么用

  • 临床医生与实验室专家紧密合作,将当前检测的优势与局限性转化为适当的临床解释标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past three decades, laboratory medicine has significantly evolved thanks to technological advances made possible by new materials and evidence. Clinicians' ongoing requests for powerful, rapid, and minimally invasive tests has led manufacturers to develop rapid, accurate, and sensitive tests that can increase diagnostic accuracy and improve follow-up, bringing laboratory medicine ever closer to personalized medicine. The aim of this study was to critically review the main problems of the current Tg and CT biomarkers for the diagnosis/monitoring of DTC and MTC, respectively, and to identify the advantages and challenges of using the new laboratory biomarkers in the clinical management of patients with differentiated and medullary thyroid cancer. Insufficient harmonization of Tg and CT assays and lack of interchangeability of laboratory results and cutoff values pose challenges for comparability and standardization of procedures and methods. New diagnostic and monitoring approaches such as PCT or the Tg doubling time have proven to be effective. Close collaboration between clinicians and laboratory specialists remains essential to translate the advantages and limitations of current assays into appropriate clinical interpretation criteria. Over the years, the journal Clinical Chemistry and Laboratory Medicine (CCLM) has taken many steps to develop advanced research and technology in the diagnosis and monitoring of tumor cancer and to help clinicians translate it into clinical practice.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Garo ML, Campennì A, Petranovic-Ovcaricek P, et al. Evolution of thyroid cancer biomarkers: from laboratory test to patients' clinical management. Clin Chem Lab Med. 2022. PMID: 36370420. doi:10.1515/cclm-2022-1087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。